BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 مايو 2025 16:01:00 بحسب Nasdaq GlobeNewswire

First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study

13 مايو 2025 07:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

12 مايو 2025 07:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

07 مايو 2025 07:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Reports First Quarter 2025 Financial Results and Business Updates

29 أبريل 2025 16:01:00 بحسب Nasdaq GlobeNewswire

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

28 أبريل 2025 05:00:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

22 أبريل 2025 07:30:36 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

11 أبريل 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

31 مارس 2025 10:00:00 بحسب Nasdaq GlobeNewswire

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM

27 مارس 2025 07:00:00 بحسب Nasdaq GlobeNewswire

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

24 مارس 2025 07:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21 مارس 2025 16:00:00 بحسب Nasdaq GlobeNewswire

BridgeBio Announces CFO Succession

17 مارس 2025 16:01:00 بحسب Nasdaq GlobeNewswire

BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

26 فبراير 2025 02:49:38 بحسب Nasdaq GlobeNewswire

BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt

24 فبراير 2025 16:09:42 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update

20 فبراير 2025 07:30:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025

13 فبراير 2025 16:01:00 بحسب Nasdaq GlobeNewswire

BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM

11 فبراير 2025 09:21:48 بحسب Nasdaq GlobeNewswire

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

13 يناير 2025 11:00:00 بحسب Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

08 يناير 2025 07:30:00 بحسب Nasdaq GlobeNewswire